Literature DB >> 21564159

TP receptor antagonists (TXRAs): expensive irrelevance or wonder drugs strangled at birth?

J M Ritter.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21564159      PMCID： PMC3099365          DOI： 10.1111/j.1365-2125.2011.03985.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

Review 1.  Endothelium-derived contracting factors.

Authors:  T F Lüscher; C M Boulanger; Y Dohi; Z H Yang
Journal:  Hypertension       Date:  1992-02       Impact factor: 10.190

2.  Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis.

Authors:  Pierre-François Lesault; Laurent Boyer; Gabriel Pelle; Ala Covali-Noroc; Dominique Rideau; Servais Akakpo; Emmanuel Teiger; Jean-Luc Dubois-Randé; Serge Adnot
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.

Authors:  Laurent Belhassen; Gabriel Pelle; Jean-Luc Dubois-Rande; Serge Adnot
Journal:  J Am Coll Cardiol       Date:  2003-04-02       Impact factor: 24.094

4.  Indomethacin and aspirin abolish prostaglandin release from the spleen.

Authors:  S H Ferreira; S Moncada; J R Vane
Journal:  Nat New Biol       Date:  1971-06-23

Review 5.  Aspirin and steroids: new mechanistic findings and avenues for drug discovery.

Authors:  Derek W Gilroy; Mauro Perretti
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

6.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.

Authors:  C Patrono; G Ciabattoni; E Pinca; F Pugliese; G Castrucci; A De Salvo; M A Satta; B A Peskar
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

7.  The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.

Authors:  A J Cayatte; Y Du; J Oliver-Krasinski; G Lavielle; T J Verbeuren; R A Cohen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-07       Impact factor: 8.311

8.  Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.

Authors:  K Takahashi; T M Nammour; M Fukunaga; J Ebert; J D Morrow; L J Roberts; R L Hoover; K F Badr
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

9.  Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man.

Authors:  D J Heavey; S E Barrow; N E Hickling; J M Ritter
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more
  1 in total

1.  Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease.

Authors:  Nan Wang; Kimberly C Vendrov; Brian P Simmons; Robert N Schuck; George A Stouffer; Craig R Lee
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-11-16       Impact factor: 3.072
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.